Abstract Acquired aplastic anemia (AA) is a rare disease with a complex pathogenesis. In most cases, T cellmediated immune destruction of hematopoietic cells results in peripheral blood pancytopenia and bone marrow hypoplasia. A subset of the heterodimeric interleukin-23 receptor gene (IL-23R) is significantly associated with autoimmunemediated diseases. To examine whether IL-23R single nucleotide polymorphisms (SNPs) might contribute to AA, we selected three IL-23R SNPs with amino acid changes (rs11209026: p.Arg381Gln; rs41313262: p. Val362Ile; and rs11465797: p.Thr175Asn) and compared their frequencies in 279 AA patients and 184 ethnically matched healthy controls. The three SNP prevalences were similar between the AA patients and controls. The Arg381Gln variant, which has a strong protective effect against inflammatory bowel disease, showed no association with AA. Furthermore, IL-23 levels in sera were measured in the AA patients and in controls, and there were no significant differences among them. Our results indicate that these three IL-23R SNPs and serum IL-23 level have no apparent impact on susceptibility to AA.
Introduction
Acquired aplastic anemia (AA) is the paradigm of the human bone marrow failure syndromes [31] . In most cases, peripheral blood and marrow of AA patients contain elevated numbers of activated cytotoxic lymphocytes, which decrease with successful immunosuppressive therapy, implicating T cell-mediated immunity in hematopoietic cell destruction. In almost all AA patients, a decreased number of regulatory T cells (Tregs) has been observed, as in other autoimmune diseases [25] . Increased levels of T-bet (a member of the T-box transcription family) in patients' T cells are responsible for the increased interferon-γ (IFN-γ) levels and the T helper type 1 (Th1) shift of CD4 + T cells in AA [24] . T-bet-mediated IFN-γ elevation would be a trigger for endogenous stimulation in T cells of AA patients as IFN-γ is a master cytokine of the Th1 immune response.
Interleukin-23 (IL-23), a member of the IL-12 family, has pro-inflammatory and immunoregulatory activities. IL-23 signaling pathway molecules may be important candidate genes for autoimmune disease [13, 27] . The IL-23 receptor is a heterodimeric complex formed by an IL-12Rβ1 subunit (shared with IL-12) and a unique IL-23R subunit [16] . Although IL-23 and IL-12 as well as their receptors share structural and functional similarities, IL-23 has biological activities in the T cell-mediated immune response similar to but distinct from IL-12. IL-23 promotes the development of T helper cells (Th17) producing IL-17, a pro-inflammatory cytokine with many targets and multiple downstream mediators [3, 12] . Elevated IL-17 levels have been observed in sera and target tissues of various autoimmune diseases and inflammatory conditions, including rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE), asthma, the two common forms of inflammatory bowel disease (IBD) (Crohn's disease [CD] and ulcerative colitis [UC]), bacterial pneumonia, and in murine experimental autoimmune encephalopathy [32] .
A recent genome-wide association study revealed that several single nucleotide polymorphisms (SNPs) in the IL-23R gene (chromosome 1p31; GenBank accession number: NM_144701.2, GeneID: 149233) were significantly associated with IBD: an uncommon coding variant (rs11209026, c.1142G>A, p.Arg381Gln) conferred strong protection against CD [8] ; several other noncoding variants in the IL-23R gene were also associated with CD and UC. Subsequent studies have also provided more evidence for an association of IL-23R gene with IBD in both adult and child cohorts [4, 7, 14, 15, 19, 26, 29] and further with other immunemediated disorders [6] , such as psoriasis and ankylosing spondylitis [5, 21] . Accumulating data indicate that genetic risk factors may be shared among various autoimmune diseases. This study is the first attempt to assess the possible contribution of IL-23R gene polymorphisms to AA.
Materials and methods

Patients and controls
Peripheral blood (PB) samples were obtained from 279 unrelated consecutive patients diagnosed with AA (133 females and 146 males), according to the criteria of the International Agranulocytosis and AA Study. These AA patients were treated at a single institution (Hematology Branch, National Heart, Lung, and Blood Institute, National [18] served as controls. Patients or their guardians provided written informed consent for genetic testing, according to protocols approved by the institutional review board of the National Heart, Lung, and Blood Institute.
DNA amplification and sequencing DNA was extracted from PB mononuclear cells using the Qiagen DNA extraction kit and subjected to polymerase chain reaction amplification using the LA Taq polymerase kit (Takara, Otsu, Japan) and adequate primer sets in order to obtain DNA fragments containing SNPs (rs11209026, rs41313262, and rs11465797). Primers for rs11209026 and rs41313262: 5′-GAGCAGAGTAAAGAGAATAGTAA-3′ ( f o r w a r d ) , 5 ′ -T G G G C T G A G G A C T TA G C C T C T TTAAGCCTC-3′ (reverse); primers for rs11465797: 5′-CAAGTAACTGGGATTACAGGCACATG-3′ (forward), 5′-CTTTACCTATATCATCCAGGTG-3′ (reverse). Sequence analysis of the amplified DNA product was performed using the BigDye Terminator version 3.1 ready reaction kit and the ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Sequencing primers are 5′-GACATTTGTAGAGAGTTTGGCATG-3′ for rs11209026 and rs41313262 and 5′-CTTCCATGC CTAGTGCGTTTGCTG-3′ for rs11465797. Sequencing data were aligned and compared using the SeqMan program (DYNASTER, Madison, WI, USA).
Cytokine enzyme-linked immunosorbent assay Sera were obtained from 23 AA patients with IL-23R polymorphisms, 37 AA patients without polymorphisms, and 21 healthy controls. IL-23 serum levels were measured using the human IL-23 heterodimer enzyme-linked immunosorbent assay (ELISA) kit (BioSource, Camarillo, CA, USA), following the manufacturer's recommendations. All samples were assayed in duplicate.
Statistical analysis
Summary statistics, such as proportions and p values, were used to describe the related variables. Statistical analysis was performed by chi square tests with a significance level of p<0.05 for SNPs and for ELISA data. All numerical results were computed using Splus 8 (TIBCO software Inc, Palo Alto, CA, USA) and NCSS, PASS, and GESS (NCSS, Kaysville, UT, USA) for Windows statistical software.
Results and discussion
To assess the contribution of IL-23 SNPs to AA susceptibility and phenotype, we first targeted the nonsynonymous rs11209026 SNP (c.1142G>A, p.Arg381Gln) because of its strong association with IBD [10] . In addition, we examined allele frequencies of two nonsynonymous SNPs, rs41313262 (c.1084G>A, p.Val362Ile) and rs11465797 (c.524C>A, p.Thr175Asn). Genotype frequencies of the three IL-23R polymorphisms examined in AA patients and healthy controls are shown in Table 1 We performed ELISA analysis to measure IL-23 levels in sera of 23 AA patients with SNP polymorphisms and 37 AA patients without polymorphisms and compared the results with those of 21 healthy controls (Fig. 1 ). There were no statistical differences among the three groups, even after stratifying AA patients according to treatment status. Collectively, our data indicate that the Arg381Gln SNP did not correlate with susceptibility of AA.
The IL-23/IL-17-mediated inflammatory axis has been implicated in numerous autoimmune diseases and inflammatory conditions. A series of cytokines, including IL-6, IL-21, TGF-β, and IL-23, sequentially or synergistically induce Th17 lineage cells, together with the cooperative action of transcription factors [11] . Conversely, other cytokines, including IL-2, IL-4, IFN-γ, and IL-27, antagonize differentiation of the Th17 lineage and inhibit IL-17 and IL-23 production. In AA patients, increased production of type 1 cytokines (IFN-γ, TNF, and IL-2) from T cells has been observed, implicating the hematopoietic cell destruction by a Th1 T cell response [9, 23] , which includes both the Fas-mediated cell death and the inhibition of hematopoietic stem cell proliferation [30] . Our previous work has suggested that T-bet-mediated IFN-γ elevation is responsible for the Th1 shift of CD4 + T cells in AA patients. As CD4 + effecter T cells were shifted to Th1 cells in AA patients, the IL-23/IL-17-mediated inflammatory axis might be suppressed in AA due to the antagonistic effect of Th1 cytokines on Th17 differentiation and development. Therefore, it is consistent that IL-23R SNPs have no significant association with AA, although it cannot be excluded that other IL-23R SNPs as well as IL-23R isoforms (differentially expressed in distinct cell types) might play protective roles.
In other autoimmune diseases such as MS, RA, and SLE, similar results have been obtained; IL-23R polymorphisms had no significant correlation with susceptibility or severity of disease [2, 17, 22] , which is in agreement with our results. It has been suggested that the IL-23R polymorphisms might play a more important role in regulating local inflammation, as in IBD and psoriasis, rather than in systemic inflammation in RA and SLE, supported by some work in mouse models [28] . Furthermore, the IL-23 pathway molecules have no association with SLE; type I cytokines, which are not induced with IL-23, are relevant in the development and maintenance of this disease [1, 20] . AA patients may share a common background of genetic risk affecting disease development and severity, which may be similar to some other autoimmune diseases and completely different from others. Further genetic studies are required to investigate as yet unidentified causal genetic alleles responsible for AA.
